Nandini Vijaisimha

Nandini Vijaisimha, with her deep-rooted expertise and passion, now stands as the Senior Director of India Corporate Affairs at MMS. In this pivotal role, she oversees and orchestrates the company’s corporate affairs strategies within the Indian context. Her activities encompass government and regulatory relations, corporate communications, and stakeholder engagement, ensuring that MMS’s values and objectives resonate in the region.

Her prior Director of Human Resources and Administration role has equipped her with a unique perspective, having managed cross-functional teams and strengthened HR processes. Nandini’s global interactions have allowed her to foster a cohesive alignment between teams scattered around the world, a skill she continues to leverage in her current role as she bridges MMS’s operations between India and its global counterparts.

Education and professional development have always been at the forefront of Nandini’s journey. She proudly holds a master’s diploma in Personnel Management and Industrial Relations from Bangalore University, India. Further amplifying her credentials, she also possesses an MBA in Human Resource Management from XLRI, Jamshedpur, India, and a bachelor’s degree in arts from Bangalore University. Her multiple HR certifications, coupled with international certification in executive coaching, serve as a testament to her unwavering commitment to ongoing education and professional excellence.

Beyond her academic and corporate achievements, Nandini boasts significant experience in coaching leaders, students, and professionals. Her expertise is particularly pronounced in the realm of Women Empowerment coaching, reflecting her dedicated approach to fostering growth and resilience in every individual she mentors.

Suggested For You

perspectives

February 13th, 2025

Helping European Drug Development Companies Succeed in the US Market

news

February 12th, 2025

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

perspectives

January 30th, 2025

Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned

perspectives

January 21st, 2025

REMS Modifications and Revisions: A Retrospective from the Past 12 Months

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan

perspectives

January 9th, 2025

How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA

perspectives

January 2nd, 2025

Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations

perspectives

December 17th, 2024

Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs

perspectives

December 11th, 2024

Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs

regulatory intelligence

December 4th, 2024

FDA Issues Detailed Guidance on Development of Gene Therapy Products

news

December 4th, 2024

AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium